Alps Advisors Inc. increased its stake in Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) by 24.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,850 shares of the company’s stock after buying an additional 17,920 shares during the period. Alps Advisors Inc.’s holdings in Aralez Pharmaceuticals were worth $297,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of Montreal Can acquired a new stake in Aralez Pharmaceuticals during the second quarter worth about $100,000. Geode Capital Management LLC acquired a new stake in Aralez Pharmaceuticals during the first quarter worth about $273,000. Integre Asset Management LLC purchased a new stake in shares of Aralez Pharmaceuticals during the first quarter valued at about $291,000. Franklin Street Advisors Inc. NC increased its stake in shares of Aralez Pharmaceuticals by 184.0% in the second quarter. Franklin Street Advisors Inc. NC now owns 168,991 shares of the company’s stock valued at $558,000 after buying an additional 109,491 shares during the period. Finally, Rubric Capital Management LLC purchased a new stake in shares of Aralez Pharmaceuticals during the first quarter valued at about $843,000. Institutional investors and hedge funds own 49.63% of the company’s stock.
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded down 2.83% during mid-day trading on Thursday, hitting $4.81. 571,721 shares of the stock were exchanged. Aralez Pharmaceuticals Inc. has a one year low of $3.10 and a one year high of $8.59. The company’s market cap is $313.81 million. The company has a 50-day moving average price of $5.27 and a 200-day moving average price of $4.21.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.08. The firm had revenue of $12.60 million for the quarter, compared to analyst estimates of $9.70 million. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. The company’s revenue for the quarter was up 142.3% on a year-over-year basis. On average, analysts predict that Aralez Pharmaceuticals Inc. will post ($1.06) earnings per share for the current fiscal year.
Several analysts have issued reports on ARLZ shares. Guggenheim reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Aralez Pharmaceuticals in a research report on Monday, August 15th. Chardan Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aralez Pharmaceuticals in a research report on Sunday, August 14th.
In related news, Director Robert Paul Harris sold 150,000 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $5.82, for a total value of $873,000.00. Following the completion of the sale, the director now directly owns 669,094 shares in the company, valued at approximately $3,894,127.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 6.77% of the company’s stock.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Want to see what other hedge funds are holding ARLZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ).
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.